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Intracellular Toll-like receptor 3 (TLR3), TLR7, and
TLR9 localize in endosomes and recognize single-
stranded RNA and nucleotides from viruses and
bacteria. This interaction induces their conforma-
tional changes resulting in the production of proin-
flammatory cytokines and upregulation of cell surface
molecules. TLR9 requires a proteolytic cleavage for
its signaling. Here, we report that myeloid and plas-
macytoid dendritic cells (DCs) deficient for the aspar-
agine endopeptidase (AEP), a cysteine lysosomal
protease, showed a decrease in the secretion of
proinflammatory cytokines in response to TLR9 stim-
ulation in vitro and in vivo. Upon stimulation, full-
length TLR9 was cleaved into a 72 kDa fragment and
this processing was strongly reduced in DCs lacking
AEP. Processed TLR9 coeluted with the adaptor
molecule MyD88 and AEP after size exclusion chro-
matography. When expressed in AEP-deficient DCs,
the 72 kDa proteolytic fragment restored TLR9
signaling. Thus, our results identify an endocytic
protease playing a critical role in TLR processing
and signaling in DCs.
INTRODUCTION
Toll-like receptors (TLRs) recognize microbial products and play
an essential role in innate and adaptive immunity. They belong to
the type I transmembrane protein family that contains a leucine-
rich repeat in an extra cellular loop and a Toll-interleukine-1 (IL-1)
receptor (TIR) homology domain in the cytoplasmic tail (Bell
et al., 2003). TLRs are divided in two families: TLR1, 2, 4, 5, 6,
and 11, which sense the presence of proteins and lipids from
bacteria and are expressed at the plasma membrane; and
TLR3, 7-8, and 9, localized in endosomes (Kawai and Akira,
2006; Kim et al., 2008), which engage single-stranded and
double-stranded RNA and unmethylated CpG DNA, respec-
tively, from pathogens. In the absence of stimulation, TLR9 is
retained in the endoplasmic reticulum (ER) together with another
ER-resident protein, UNC93B (Brinkmann et al., 2007). Uponstimulation with CpG DNA, it relocates to the endo-lysosomal
compartment, allowing the recruitment of the adaptor molecule,
MyD88, and thereafter, signals. Recently it was demonstrated
that in macrophages, after stimulation, TLR9 is cleaved into
a C-terminal fragment and that this cleaved form alone is compe-
tent for signaling (Ewald et al., 2008). This is an important step
indeed, because it is the activation of the MyD88 signaling
pathway that leads to the production of proinflammatory cyto-
kines and cell surface expression of costimulatory molecules in
dendritic cells (DCs) (Hemmi and Akira, 2005; Kaisho and Akira,
2001). It has further been shown that interfering with the pH by
blocking lysosomal acidification inhibits TLR7 and 9 signaling
(Yi et al., 1998), suggesting a role for endocytic proteases in
endosomal TLR stimulation.
Lysosomal proteases, which are highly dependent on the pH
for their activities, can be classified into three major classes:
aspartic, serine, and cysteine protease families. Asparagine
endopeptidase (AEP) or mammalian legumain is an aspara-
gine-specific cysteine protease that has been implicated in the
MHC class II presentation pathway. AEP initiates the processing
of tetanus toxin in human B cells, destroys an immuno-dominant
peptide of myelin basic protein (MBP, 85-99), and performs the
early steps of degradation of the invariant chain (Ii) in human
B-EBV cells (Manoury et al., 1998, 2002, 2003). AEP is unrelated
to the papain-like cysteine protease family such as cathepsins B
(CatB) and L (CatL); it is grouped together with the caspases,
separases, and some bacterial proteases in clan CD (Chen
et al., 1997, 1998; Uhlmann et al., 2000). Unlike other lysosomal
cysteine proteases, AEP is insensitive to leupeptin and cleaves
on the carboxy-terminal sides of asparagine residues. AEP is
synthesized as a 56 kDa precursor and targeted to the endocytic
pathway. In the lysosomal compartments, N- and C-terminal
propeptides are auto-cleaved to generate a 46 kDa mature
form, which can be further processed into a 36 kDa fragment
(Li et al., 2003). Acidic pH is a prerequisite for maturation of
AEP, and therefore its greatest activity is found in lysosomal
compartments. AEP is constitutively expressed in most cell
types, especially in macrophages and DCs. Recent published
findings have centered around cysteine proteases (in particular
cathepsin K and cathepsin L) in endosomal TLR activation
(Asagiri et al., 2008; Matsumoto et al., 2008; Park et al., 2008).
However, no direct biochemical evidence in DCs for TLR9
cleavage by cathepsin L or cathepsin K was brought forward inImmunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc. 737
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TLR9 Signaling Requires AEPFigure 1. Digestion of 35S-Labeled TLR9 with Purified AEP or Disrupted Lysates from WT or AEP-Deficient BMDCs
(A) Tlr9 cDNA was transcribed and translated in vitro in the presence of rabbit reticulocyte and 35S-Met. 35S-Met-labeled TLR9 protein was digested or not with
20 mg of WT cell lysate in the absence or presence of the indicated inhibitors for 4 hr.
(B) Scheme of murine TLR9 protein (Uniprot accession number Q9EQU3). The 26 LRRs and recognition domain of polyclonal rabbit TLR9 (Santa Cruz) are
represented as well as the putative Asn cleavage site, pI, and MW of fragments.
(C) Same reaction as (A) via WT (lane 2) or AEP-deficient (KO, lane 3) DC lysate (left). Graphs show mean ± SD (n = 3) via one-way ANOVA test. **p < 0.01 (right).
(D) Same digestion experiments with different doses of rAEP (7.5U, lane 2; 15U, lane 3). The reactions were performed in 50 mM citrate buffer, 0.1% CHAPS
(pH 5.5) and separated on a 10% SDS-NuPAGE. ND, nondigested.
Representative data from three independent experiments.those studies. With this in mind, we decided to investigate
whether AEP was required for TLR9 response. Here, we showed
that full-length TLR9 was a substrate for AEP both in vitro and in
living cells. Blocking AEP activity by knocking down its gene
decreased the appearance of TLR9 proteolytic fragments of 36
and 72 kDa in murine DCs, resulting in reduced TLR9 signaling
after CpG stimulation in cells and in AEP-deficient (Lgm/)
mice. Our resulting findings suggest that AEP plays a major role in
TLR9 signaling in DCs.
RESULTS
AEP Can Cleave TLR9 In Vitro
To analyze the processing of TLR9 in vitro, we incubated radiola-
beled translated TLR9 with lysate of wild-type (WT) bone-
marrow-derived DCs (BMDCs) as a source of proteases. The
full-length TLR9 protein was digested to produce one major
band that migrates around 36 kDa (Figure 1A), corresponding
probably to the N-terminal part of TLR9 (TLR9 N-ter) (Figure 1B)
previously described (Park et al., 2008). We then used various
protease inhibitors to identify the enzymes involved in TLR9738 Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc.degradation in vitro. In the presence of leupeptin (a broad inhibitor
of cysteine proteases except AEP), full-length TLR9 was digested
to generate a fragment different from the TLR9 N-ter migrating
at a higher molecular weight (Figure 1A). In contrast, addition of
MV026630, previously described to specifically inhibit AEP
(Loak et al., 2003; Manoury et al., 2003), showed a clear inhibition
of the production of the TLR9 N-ter product (Figure 1A). To inves-
tigate this further, we used lysate from WT and AEP-deficient
BMDCs as a source of proteases. Proteases contained in both
lysates were able to degrade full-length TLR9 (Figure 1C), but
those expressed in AEP-deficient BMDC lysate digested TLR9
less efficiently than WT lysate. Longer exposure of the radioactive
film showed that both lysates could cleave TLR9 into fragments
(Figure S1A available online) among which two of them migrate
at 72 and 36 kDa corresponding probably to the N- and C-
terminal part of TLR9 fragments (Figure 1B). To test whether
AEP could directly cleave TLR9, TLR9 was incubated with
recombinant AEP, at different doses. Recombinant AEP was
able to cleave TLR9 into fragments, one of them being the TLR9
N-ter (Figure 1D). As previously described (Ewald et al., 2008;
Park et al., 2008), cathepsins K (CatK), L (CatL), and S (CatS)
Immunity
TLR9 Signaling Requires AEPFigure 2. Lack or Severe Delay of TLR9 Processing in Phagosomal Compartments Purified from AEP-Deficient Cells
(A) Phagosomes from WT or AEP-deficient (KO) BMDCs were magnetically purified after 20 min or 2 hr. Proteins expressed either in total lysate (50 mg) or in
phagosomes (5 mg) were resolved by SDS-PAGE. Early (TfR) and late (LAMP2) markers were visualized by immunoblot.
(B and C) Immunodetection of TLR9 proteins in early and late phagosomes from WT or AEP-deficient (KO) BMDCs unstimulated (B) or stimulated (C) with CpG.
(D) Same experiments as described in (A) in phagosomes purified from Tlr9/ DCs.
Data are representative of three experiments.were also able to cleave TLR9 in vitro (Figure S1B) and more
efficiently than AEP or CatB. These results show that in vitro,
AEP contributes to TLR9 processing and suggest that AEP might
play a role in TLR9 processing in living cells.
Compromised TLR9 Cleavage in AEP-Deficient DCs
TLR9 resides in the ER in resting cells and upon stimulation
translocates to the endo-lysosomal compartment where it
signals. To look at endogenous TLR9 cleavage and intracellular
location, we purified phagosomes from WT and AEP-deficient
DCs fed with latex beads. As expected, early phagosomes puri-
fied after 20 min of pulse with latex beads were enriched in trans-
ferin receptor protein (TfR) (Figure 2A, top) and, in contrast, late
phagosomes (20 min of pulse followed by 100 min of chase)
accumulated LAMP2 protein (Figure 2A, bottom). At the steady
state, a TLR9 cleavage fragment of approximately 72 kDa size
was observed only in late WT phagosomes (Figure 2B). We
designated this fragment as being the C-terminal segment of
TLR9 containing at least the last 400 amino acids, based on
the recognition site of TLR9 antibody that maps between amino
acids 771 and 800 (Figure 1B) and previous experimentsshowing the accumulation of this TLR9 cleavage fragment in
phagosomes purified from raw cells (Ewald et al., 2008). In the
presence of CpG, TLR9 cleavage occurred much more rapidly
and was already detectable after 20 min of CpG stimulation
(Figure 2C). In the absence of AEP, no TLR9 processing fragment
was observed at the steady state in either early or late phago-
somes (Figure 2B). We did detect the 72 kDa TLR9 cleavage
fragment in CpG-stimulated AEP-deficient cells, but at a lower
amount and only in late phagosomes (Figure 2C). As expected,
no proteins—neither full length nor fragmented—were observed
in phagosomes purified from TLR9-deficient (Tlr9/) DCs
(Figure 2D). Altogether, these results show that after CpG stimu-
lation, the generation of the TLR9 C-terminal fragment is strongly
delayed in phagosomes purified from AEP-deficient cells.
We were not able to detect the adaptor molecule MyD88 either
in WT and AEP-deficient phagosomes. Thus, to investigate
whether the adaptor MyD88 molecule interacted or coeluted
with the processed form of TLR9 in WT and AEP-deficient
DCs, we stimulated cells with and without TLR9 ligand for
30 min and then fractionated TLR9 and MyD88, on the basis of
size exclusion chromatography. In three separate experiments,Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc. 739
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TLR9 Signaling Requires AEPcomprising 18 samples, quantitatively similar profiles of total
lysate from WT and AEP-deficient cells were obtained (Fig-
ure S2). Size exclusion chromatography separated high molec-
ular weight components into two major peaks where UV absor-
bance was detected. Peak 1 (fractions 12 to 18), corresponds
to proteins that eluted at a high molecular weight ranging from
800 to 2000 kDa. Full-length TLR9 (130 kDa), as well as
other polypeptides that most likely correspond to dimers or
complexes of TLR9 (200 kDa) that resist to nonreducing condi-
tions used here (Figure 3A), were detected in these fractions in
WT and AEP-deficient BMDCs at the steady state. We next
investigated the fate of TLR9 after CpG treatment. After 30 min
of CpG stimulation, full-length TLR9 was still observed in frac-
tions 12 to 18 (Figure 3B) from WT DCs, but also, a TLR9
cleavage fragment of approximately 72 kDa size was detected
in fractions 36 to 41 corresponding to proteins of molecular
weight of approximately 70 to 200 kDa. In the absence of AEP,
after CpG stimulation, we did not detect this 72 kDa TLR9-pro-
cessed fragment (Figure 3B). In these cells, we consistently
observed an accumulation of uncleaved full-length TLR9 (Fig-
ure 3B). Same results were obtained after 60 min of CpG stimu-
lation (data not shown). We then investigated whether or not the
adaptor MyD88 molecule coeluted with the processed form of
TLR9 (fractions 36 to 41) in WT DCs. Indeed, we were able to
detect MyD88 in these fractions (36–41, Figure 3B). In contrast,
we were unable to detect any coelution between MyD88 and
full-length TLR9 either in WT or AEP-deficient DCs both at steady
state and after CpG stimulation (Figures 3A and 3B, fractions 12
to 18). After 30 min of CpG stimulation, we observed a substantial
enrichment in the amount of 72 kDa TLR9 fragment (in fraction
40) in WT compared to AEP-deficient BMDCs (Figure 3C). No
TLR9 protein, neither full length nor fragmented, was detected
in fractionated Tlr9/ cells at the steady state or stimulated
with CpG (Figure S3). Additionally, in LPS-activated cells, no
cleavage of TLR9 was observed in the fractions 41–49 where
MyD88 was detected (Figure S4). Taken together, these results
demonstrate that CpG stimulation induces a TLR9 cleavage
product of 72 kDa that coelutes with MyD88 in WT cells, and
that at early time points of CpG stimulation, AEP-deficient DCs
fail to process TLR9, suggesting an impaired association
between cleaved TLR9 and the adaptor molecule MyD88 in these
cells.
CpG Boosts the Recruitment and Activity of AEP
and Decreases the Endosomal pH
The above results suggested that TLR9 processing might occur
more rapidly after CpG stimulation. We hypothesized that CpG
induced the recruitment and/or a boost in protease activities
that promote TLR9 cleavage. To address this question, we
measured the recruitment and/or activity of AEP both in cells
and in endo-lysosomal compartments after CpG stimulation.
At steady state, AEP was coeluted with MyD88 (Figure 3A, frac-
tions 36–41) and not with full-length TLR9 (Figure 3A, fractions
12–18). After TLR9 stimulation, enhanced mature AEP was
detected in the same fractions where TLR9 cleavage fragment
accumulated (Figure 3B, fractions 36–41). No AEP was detected
in AEP-deficient DCs (Figures 3A and 3B). Upon CpG stimula-
tion, there was a substantial accumulation of AEP in the same
fraction where the C-terminal TLR9-processed fragment740 Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc.appears (Figure 3C). Furthermore, coelution of AEP with pro-
cessed TLR9 and MyD88 correlated with a strong increase in
AEP activity observed in both total cell extracts and endosomes,
where cleavage of TLR9 occurred after CpG stimulation (Fig-
ure 3D). Thus, CpG stimulation increases AEP activity and
recruitment in compartments where TLR9 is cleaved.
Because AEP is active at low pH, we analyzed whether this
boost in AEP activity correlates with an increased acidification
in endosomes and lysosomes. We observed a dramatic acidifi-
cation of the endocytic pathway upon TLR9 activation in WT
and AEP-deficient DCs (Figure 3E). As expected, drugs inter-
fering with pH acidification, such as concanamycin B (data not
shown), completely blocked TLR9 signaling (Figure 3F). Thus,
TLR9 processing requires low pH and AEP activity.
AEP Is Required for Full Cytokine Production in DCs
The above results suggested that the lack of AEP activity might
decrease TLR9 signaling. To address this question, WT and
AEP-deficient BMDCs were stimulated with TLR4 and TLR9
agonists. We observed a significant decrease in tumor necrosis
a (TNF-a) and interleukin 6 (IL-6) secretion by AEP-deficient DCs
upon TLR9 engagement, but not when TLR4 was stimulated
(Figures 4A and 4B). Similar results were obtained when we
used DCs preincubated with MV026630 (data not shown). In
contrast, we did not observe any difference in TNF-a secretion
when WT or AEP-deficient macrophages were stimulated with
TLR4 or TLR9 agonists (Figure S5). We next investigated whether
the TLR9 C-terminal fragment, which contains the cytoplasmic
TIR domain that interacts with MyD88, was able to initiate
TLR9 signaling. As previously described (Park et al., 2008), the
C-terminal fragment of TLR9 was sufficient to initiate signaling
to the same level as full-length TLR9 when expressed in Tlr9/
DCs (Figure 4C). Neither C-terminal nor full-length TLR9 could
restore signaling in cells lacking MyD88 (Figure 4D). Importantly,
AEP-deficient DCs transfected with cDNA encoding the
recombinant C-terminal TLR9 product regained responsiveness
to the same level as WT cells after CpG stimulation, as indicated
by IL-6 secretion (Figure 4E, left). As shown above, after TLR9
stimulation, diminished IL-6 production was detected when
AEP-deficient DCs were transfected with cDNA encoding GFP
control plasmid or GFP-tagged full-length TLR9 (Figure 4E, left)
as compared to WT cells. Furthermore, transfection of cDNAs
coding for AEP and GFP in AEP-deficient DCs restore IL-6 secre-
tion after TLR9 stimulation (Figure 4E, left). Same results were
obtained when IL-12p40 expression was measured (Figure 4E,
bottom). As a control, LPS-stimulated cells either transfected
with GFP, full-length, or C-terminal TLR9 plasmids secreted
same amount of IL-6 and IL-12p40 (Figure 4E, right panels).
We conclude that AEP plays a critical role in TLR9 signaling in
DCs and that the C-terminal TLR9 fragment alone is sufficient
to restore signaling in AEP-deficient DCs to the same level as
in WT cells, requiring the adaptor molecule MyD88.
Altered CpG Adjuvancy in AEP-Deficient Mice
To examine the role that AEP might play in vivo in TLR9 signaling
in DCs, we assessed the ability of AEP-deficient DCs to secrete
proinflammatory cytokines and to prime naive CD4+ T cells. It
has been shown that cytokines are mainly secreted in vivo by
CD11c+ DCs in the early hours after TLR agonist injection in
Immunity
TLR9 Signaling Requires AEPFigure 3. CpG Induces TLR9 Processing in an AEP-Dependent Fashion and a Rapid Decrease of Endosomal pH in WT and AEP-Deficient
Dendritic Cells
(A and B) Lysates from WT (left) or AEP-deficient (KO) BMDCs (right) treated (B) or not (A) with CpG (10 mg/ml) for 30 min, were applied to a size exclusion resin and
eluted with 150 mM NaCl, 50 mM Tris (pH 7.4), 5 mM MgCl2. Fractions were collected and were analyzed (5 mg) on a 10% Bis-Tris NuPAGE gel. TLR9, MyD88, and
AEP proteins were visualized by immunoblot with TLR9-, MyD88-, and AEP-specific antibodies.
(C) Quantification of the fold of increase of the TLR9 processing fragment (C-ter), MyD88, and AEP proteins present in fraction 40 upon CpG stimulation via Image
J Software. Graphs show mean ± SD (n = 3).
(D) AEP activity in total lysate and purified endosomes from WT BMDCs treated or not with CpG (10 mg/ml) for the indicated time was measured with a specific
fluorescent substrate. Graphs show mean ± SD (n = 3) via unpaired t test. *p < 0.05.
(E) Kinetic of endo-lysosomal pH in WT and AEP-deficient (KO) BMDCs pulsed for 10 min with FITC- and Alexa-647 coupled dextran in the presence or not of
10 mg/ml of CpG and chased for different times. Graphs show mean ± SD (n = 3) via unpaired t test. **p < 0.01.
(F) Effect of endosomal alkalinisation in cytokine secretion upon LPS or CpG stimulation in WT BMDCs. Graphs show mean ± SD (n = 3) via unpaired t test. ***p <
0.001.mice (Hou et al., 2008). Cytokine production from DCs in vivo
was then examined 2 hr after the mice were i.v. injected with
CpG or LPS. In WT mice, both LPS and CpG induced IL-6 andIL-12p40 secretion (Figures 5A and 5B). In contrast, we consis-
tently observed attenuated IL-6 and IL-12p40 secretion in
AEP-deficient mice after TLR9 stimulation (Figures 5A and 5B).Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc. 741
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TLR9 Signaling Requires AEPThus, in DCs, AEP is required for the secretion of inflammatory
cytokines induced by TLR9 engagement by CpG in vivo.
To monitor how decreased TLR9 signaling in AEP-deficient
DCs could affect their capacity to initiate adaptive immune
response, we measured the activation of ovalbumin (OVA)-
specific TCR transgenic OTII T cells after injection in WT and
AEP-deficient mice. First, we excluded that OVA processing
was dependent on AEP both in vitro and in vivo. Ovalbumin
degradation assays were performed as previously described
(Savina et al., 2006). As shown in Figure S6A, antigen degrada-
tion was observed over time and was equivalent in WT and
AEP-deficient BMDCs. To investigate antigen presentation of
OVA in vivo, we immunized WT or AEP-deficient mice with
OVA. Ten days later, lymph nodes were restimulated in vitro
with different OVA concentration and T cell proliferation was
measured by 3H-thymidine incorporation. OVA-specific T cell
Figure 4. AEP Activity Is Required for Full
Cytokine Production after TLR9 Stimulation
(A and B) BMDCs from WT (black bars) or AEP-
deficient (KO) (white bars) mice were stimulated
with increasing concentrations of TLR agonist
(CpG for TLR9, LPS for TLR4) for 6 hr, and secre-
tion of TNF-a and IL-6 were measured by ELISA.
Graphs show mean ± SD (n = 3) via unpaired
t test. ***p < 0.001.
(C–E) Tlr9/ (C) Myd88/ (D) AEP-deficient (KO,
white bars) and WT (black bars) (E) DCs were
transfected with cDNAs encoding GFP, GFP-
tagged full-length TLR9, or C-terminal TLR9 frag-
ment and/or AEP (gray bars) at day 8 of culture.
After transfection, cells were harvested and stimu-
lated with TLR ligands (CpG, 2 mg/ml; LPS, 10 ng/
ml) for 16 hr and secretion of IL-6 (top) and
IL-12p40 (bottom) was measured by ELISA.
Amount of IL-6 and IL-12p40 produced by unsti-
mulated cells was subtracted from CpG-stimu-
lated cells. (ND, not detected). Graphs show
mean ± SD (n = 3).
responses generated in WT or AEP-defi-
cient mice were again similar (Fig-
ure S6B). These results indicate that
OVA processing in vitro and in vivo does
not require AEP.
To evaluate the capacity of AEP-defi-
cient DCs to activate T cells in response
to TLR9 agonist in vivo, we injected
CFSE-labeled OT-II T cells into WT and
AEP-deficient mice and then immunized
them with OVA-coated beads alone or
with soluble CpG or LPS used as adju-
vants. T cell proliferation was analyzed
2 days later. In WT mice, both immuniza-
tion protocols (CpG and LPS) led to
a proliferation and an accumulation of
OT-II T cells in the spleen compared to
immunization with OVA alone (Figures
5C and 5D). In AEP-deficient mice, we
observed a normal proliferation and
accumulation of OT II T cells in response
to LPS treatment compared to WT mice (Figures 5C and 5D).
However, fewer OT-II T cells accumulated in the spleen of
AEP-deficient mice that were immunized with CpG than in the
control mice (Figure 5D). In fact, no proliferation of OT-II T cells
was seen when CpG was used as an adjuvant in AEP-deficient
mice (Figure 5C, left bottom). Thus, AEP-deficient mice show
an altered response to TLR9 in vivo, characterized by a defect
in inflammatory cytokine secretion and impaired capacity to
initiate an adaptive immune response upon TLR9 activation.
Reduced Cytokine Production in Plasmacytoid
DCs Lacking AEP
We then wondered whether this defect in TLR9 signaling in cells
lacking AEP was a specific feature of myeloid DCs. We purified
mouse and human plasmacytoid DCs, key cells in the immune
system that secrete interferon a (IFN-a) after viral infection.742 Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc.
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TLR9 Signaling Requires AEPUpon CpG stimulation, human and mouse pDCs preincubated
with MV026630 showed a substantial decrease in IFN-a produc-
tion compared to nontreated cells (Figures 6A and 6B). As previ-
ously shown, the inhibitor of PI3-kinase (LY compound) blocked
Figure 5. Impaired CpG Adjuvancy in AEP Knockout Mice
(A and B) IL-6 (A) and IL-12p40 (B) secretion were measured in serum of WT or
AEP-deficient (KO) mice after 2 hr of injection i.v. with CpG-B (25 mg) (left), LPS
(1 mg) (right), or vehicle alone (PBS). Graphs show mean ± SD (n = 3 via
unpaired t test). *p < 0.05.
(C and D) In vivo proliferation assay of congenic CFSE-labeled OTII T cells
(Thy1.1+). Lymphocytes were transferred into Thy1.2+ WT (black bars) or
AEP-deficient (KO) mice (white bars) 8 hr before injection of OVA-coated
beads i.v. with or without soluble TLR agonist. CFSE dilution and total number
of OTII cells in the spleen were measured by flow cytometry. Graphs show
mean ± SD (n = 3). Data are representative of three experiments.IFN-a secretion upon CpG stimulation (Guiducci et al., 2008) and
to the same extent as the AEP inhibitor (Figure 6B). Thus, AEP
plays a critical role in TLR9 signaling not only in myeloid DCs
but also in plasmacytoid DCs.
Cathepsin Activity Is Not Impaired in DCs Lacking AEP
To examine whether expression and activity of other cysteine
proteases might be altered by the loss of AEP as reported (Maehr
et al., 2005; Shirahama-Noda et al., 2003) and thus influence
TLR9 processing, we performed CatB, CatK, CatL, and CatS
immunoblots on samples from WT and AEP-deficient BMDCs.
Whereas the immature and mature form of CatB and the two-
chain form (heavy and light chain) of CatL were present in WT,
only the immature CatB and single-chain CatL form could be de-
tected in AEP-deficient cells (Figure 7A). No difference in CatS
expression was observed. Interestingly, CatK expression was
greatly increased in AEP-deficient cells in comparison to WT,
where it was almost undetectable (Figure 7A). Active forms of
cathepsins in BMDCs can be identified by taking advantage of
their reaction to the cysteine-protease mechanism-based probe,
DCG-04 (Lennon-Dumenil et al., 2002; Maehr et al. 2005). BMDC
lysates from WT and AEP-deficient cells were labeled with DCG-
04 and immunoprecipitated for CatB, L, and S (Figure 7B)
proteins. These data revealed that CatB, L, and S in AEP-defi-
cient cells were as enzymatically active as those in WT cells
based on their labeling with the probe DCG-04. Additionally,
by using fluorogenic substrates selective for CatB, CatB or
CatL, and CatS, we found a similar (CatB and CatS) or, in
some cases, an increased (CatB or CatL) amount of hydrolysis
of these substrates in AEP-deficient cells (Figure 7C). After
CpG stimulation, WT or AEP-deficient DCs showed an overall
enhancement in cysteine protease activity (Figure 7C). To rule
out a role for CatK in TLR9 processing in AEP-deficient cells,
we fed them with pro-CatK to see whether it could restore
TLR9 signaling upon CpG stimulation. Despite enhanced
amount of CatK in AEP-deficient cells (Figure 7D), this protease
was not able to restore IL-12p40 secretion after CpG stimulation
(Figure 7E). Altogether, these results suggest that changes in the
activity of cysteine proteases such as CatB, K, L, and S are not
responsible for decreased TLR9 response in AEP null cells.
Mutating Putative AEPCleavage Site in TLR9Decreases
TLR9 Response in Living Cells
The strict specificity of AEP can allow us to identify and mutate
protease cleavage sites in TLR9 protein. Although a 3D structure
for TLR9 is not known, secondary-structure prediction programs
are available for the residues 441–470 situated between the two
leucine-rich regions (LLR 14–15) described previously as being
part of a flexible loop susceptible to proteolysis (Park et al.,
2008). Indeed, TLR9 contains one asparagine localized in this
region that can be a putative cleavage site for AEP (Figure 1B).
To establish whether or not AEP could cleave TLR9 at this puta-
tive site, site-directed mutagenesis was performed on aspara-
gine residue 466 that was mutated to Gln (N466Q). N466Q
TLR9 was subjected to AEP digestion in vitro and was slightly
more resistant to AEP degradation than WT TLR9 (data not
shown). We next investigated whether or not this TLR9 mutant
was able to initiate TLR9 signaling. WT or N466Q TLR9 cDNAs
were transfected into Tlr9/ cells and cytokine productionImmunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc. 743
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TLR9 Signaling Requires AEPFigure 6. Impaired Cytokine Secretion upon AEP Inhibition in Plasmacytoid Dendritic Cells
(A) Spleen-derived plasmacytoid DCs were treated with or without MV026630 (20 mM) and activated with 10 mg/ml of CpG-A. IFN-a secretion was measured by
ELISA after overnight culture. Graphs show mean ± SEM (n = 3).
(B) Human pDCs isolated from fresh buffy coats were stimulated overnight with CpG-A or CpG-C (5 mg/ml) in the presence or absence of MV026630 (20 mM or at
different concentrations) or PI3K (LY, 5 mM). IFN-a secretion was measured by ELISA. Each dot corresponds to pDCs purified from one buffy coat.was measured upon CpG stimulation. Transfection efficiency
was the same for both constructs (20%) (data not shown).
We observed a clear decrease in IL-6 and IL-12p40 production
after TLR9 stimulation when TLR9 mutant was expressed in
Tlr9/ cells (Figure 7F). As a control, LPS-stimulated cells either
transfected with N466Q or WT TLR9 secreted similar amount of
IL-6 and IL-12p40 (Figure 7F). These results demonstrate that
mutating a putative AEP cleavage site in TLR9 strongly
decreases its signaling in DCs, suggesting perhaps direct
cleavage of TLR9 by AEP.
DISCUSSION
Drugs interfering with the endo-lysosomal compartments and/or
pH acidification, such as chloroquine and concanamycin B,
completely block intracellular TLR signaling (Ahmad-Nejad
et al., 2002), indicating a possible role of proteases in this
process. Although very recent work has shed light on the
cleavage of TLR9 in raw transfected cells, few biochemical and
in vivo studies exist on the nature of the protease(s) when
executing this proteolysis in DCs. We demonstrate here that
TLR9 endogenous processing in DCs is dependent on AEP. By
using cell fractionation based on protein size, we show that
TLR9 is cleaved into a C-terminal fragment that coelutes with
the adaptor protein MyD88. Specific inhibition of AEP compro-
mised TLR9 processing and shows that upon CpG stimulation
in DCs and in mice, AEP is involved in TLR9 signaling. Consistent
with this finding, we observe that TLR9 C-terminal product, once
generated, is sufficient to restore TLR9 signaling in AEP-deficient
DCs to a similar level as in WT cells.
AEP has a central role in regulating other proteases. Indeed,
AEP-deficient cells exhibit a defect in maturation of many
cathepsins (CatB, D, H, and L) in kidney and bone marrow, as
well as in spleen DCs and BMDCs (Maehr et al., 2005; Shira-
hama-Noda et al., 2003). These lysosomal proteases reach
endocytic compartments as proforms or zymogens where their
propeptide is removed proteolytically. The resulting immature
or single-chain forms are then cleaved into mature or two-chain
forms for CatB and L, respectively. AEP is involved in this latter744 Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Incevent of cathepsin maturation through a still unknown process.
Thus, the defect in TLR9 processing in AEP-deficient cells could
result from the impaired maturation of these cysteine proteases.
However, we argue against this hypothesis because: (1) activi-
ties and localization of CatB and L in AEP-null cells are
unchanged or even increased compared to WT cells, (2) leupep-
tin, a broad inhibitor of cysteine proteases except AEP, had rela-
tively little effect on TLR9 degradation in vitro, and (3) incubation
of AEP-deficient DCs with pro-CatK did not restore TLR9
signaling upon CpG stimulation despite high amount of this
enzyme in AEP-deficient cells. However, differential substrate
specificity between immature and mature cathepsins could
account for the suppressed TLR9 processing observed in
AEP-deficient cells. Interestingly, we have noticed that in Ii-defi-
cient cells which display no mature CatL, TLR9 signaling is unaf-
fected (data not shown) (Fiebiger et al., 2002; Lennon-Dumenil
et al., 2001). So, altogether these data are not in favor of a partic-
ipation of cathepsins to the impaired TLR9 signaling observed in
DCs lacking AEP.
The strict specificity of AEP has allowed us to identify and
mutate a putative AEP cleavage site in the flexible loop of TLR9
protein previously described to be susceptible to proteolysis
(Park et al., 2008). Experiments addressing the functionality of
this TLR9 mutant in TLR9-deficient cells clearly show a decrease
in TLR9 signaling when this mutant was stimulated with CpG,
suggesting a direct cleavage of TLR9 by AEP. However, we
stress that the exact AEP cleavage site(s) in TLR9 remain to be
identified. Because AEP cleaves native antigens, it is tempting
to speculate that TLR9 processing requires a first cleavage at
an Asn site in endosomes, further allowing other proteases to
process and generate a fully active TLR9 fragment in lysosomes.
This may explain why cells chemically inhibited with specific
cathepsin inhibitors or deficient for these proteases (CatB, K, L,
and S) display altered TLR9 signaling in vitro as in AEP-deficient
DCs (Asagiri et al., 2008; Ewald et al., 2008; Park et al., 2008).
Consistent with this hypothesis, we found an inhibition of IL-6
production in CatB- and L-deficient DCs but to a lesser extent
than in AEP-deficient cells (data not shown). In addition, after
15 min of stimulation, CpG induces a strong boost in AEP activity.
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TLR9 Signaling Requires AEPFigure 7. TLR9 Response Is Not Dependent on Cathepsins in AEP-Null Cells whereas Mutating a Putative AEP Cleavage Site in TLR9
Decreases Its Signaling
(A) Protein lysates (20 mg) from WT or AEP-deficient (KO) cells were immunoblotted with antibodies for CatB (top left: iCatB, immature CatB; mCatB, mature
CatB), CatK (top right: pro-CatK; mCatK, mature CatK), CatL (bottom left: SC, single chain of CatL; HC, heavy chain of CatL), and CatS (bottom right).
(B) Cysteine proteases activities from WT or AEP-deficient (KO) BMDCs were monitored with the active site labeling probe DCG-04 that react with their catalytic
site. CatB, L, and S were analyzed by immunoprecipitation from DCG-04-labeled BMDC lysates and detection of the biotinylated probe with a streptavidin-linked
HRP.
(C) Protein lysates (10 mg) of unstimulated (square) or CpG-stimulated (triangles) DCs from WT (black symbols) and AEP-deficient (KO) (white symbols) were
assayed for protease activities with specific substrates for CatB, CatB or CatL, and CatS.
(D) Immunoblot analysis for CatK expression of protein lysates from CpG-activated WT or AEP-deficient (KO) BMDCs fed or not with pro-CatK.
(E) Cells were treated as in (D) and stimulated with different concentrations of CpG for 4 hr, and IL-12p40 secretion was measured by ELISA. Graphs show mean ±
SD (n = 3) via unpaired t test. ***p < 0.001.
(F) Tlr9/ DCs were transfected with cDNAs encoding GFP-tagged full-length or N466Q TLR9 at day 8 of culture. 24 hr after transfection, cells were harvested
and stimulated with TLR ligands (CpG, 2 mg/ml; LPS, 10 ng/ml) for 16 hr, and secretion of IL-6 (left) and IL-12p40 (right) was measured by ELISA. Amount of IL-6
and IL-12p40 produced by unstimulated cells was subtracted from CpG-stimulated cells. *p < 0.05.
Data are representative of two to three experiments.Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier Inc. 745
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TLR9 Signaling Requires AEPthat is less pronounced for CatB and L. Interestingly, the increase
in cathepsins B and L activity or recruitment in lysosomes
occurred at later time points after 60 min of TLR9 stimulation.
The need for proteases in intracellular TLR activation may be
a common phenomenon. Indeed, we have evidence that TLR7
is cleaved in DCs upon imiquimod stimulation and that this
TLR7 processing might also require AEP. In other words, AEP
may be necessary for TLR7 signaling (data not shown).
We did not observe any difference in cytokine secretion when
WT or AEP-deficient macrophages were stimulated with TLR9
ligand. The reasons why TLR9 signaling does not rely on AEP
in macrophages is not clear. It is most likely that the highly
proteolytic, very acidic milieu found in the endocytic pathway
of macrophages and which is not observed in DCs negates the
dependence of signaling on single proteases. Indeed, we know
that the cleavage reported herein is also required for signaling
in macrophages (Ewald et al., 2008) and that the neutralization
of their endocytic pathway with weak bases also inhibits TLR9
signaling in these cells. In contrast, DCs bear low amounts of
lysosomal proteases (Delamarre et al., 2005; Lennon-Dumenil
et al., 2002) and inefficient endosomal and lysosomal acidifica-
tion (Jancic et al., 2007; Trombetta et al., 2003). Because AEP
is active at low pH, it is likely that the boost in AEP activity
observed upon TLR9 activation but not with TLR4 stimulation
(data not shown) results from the enhanced endo-lysosomal
acidification. In line with this, at physiological pH, TLR9 binding
to CpG DNA is weak, but lowering the pH to 6.5 or 5.5 leads to
a strong TLR9-CpG DNA interaction (Rutz et al., 2004). As
expected, drugs interfering with pH acidification, such as conca-
namycin B, completely blocked TLR9 signaling. This can be
explained either by a reduced TLR9 processing because AEP
is not active enough or/and by a direct inhibition of CpG binding
to TLR9. This would point to the conclusion that TLR9 process-
ing requires both low pH and high AEP activity. The fast pH acid-
ification upon CpG stimulation we noticed might allow AEP- and
cathepsin-dependent TLR9 cleavage to proceed, quickly
followed by a better binding of CpG to TLR9 and a change in
receptor conformation. Altogether these events are presumably
sufficient to recruit the adaptor molecule MyD88 and initiate
signaling.
TLR9 self-associates in cells and is preformed as a dimer (Latz
et al., 2007). Upon stimulation with CpG, TLR9 in association
with UNC93B relocates to the endo-lysosomal compartment,
allowing the recruitment of the adaptor molecule MyD88, and
thereafter, signaling. However, it has been suggested (Brinkmann
et al., 2007; Kim et al., 2008) that TLR9 can also traffic to endo-
somes upon LPS stimulation. We have not studied TLR9 traf-
ficking in LPS-stimulated cells, but taking in consideration that
pH and protease activities are the same as in WT cells, it seems
unlikely that TLR9 processing occurs in LPS-treated cells.
In DCs, upon receptor activation, TLR9 might be associated
within a large receptor complex containing MyD88, AEP, other
signaling molecules, and chaperones like UNC93B stabilizing
these interactions (as we saw in the size exclusion chromatog-
raphy experiment). Coimmunoprecipitation experiments need
to be addressed to confirm the interaction between cleaved
TLR9, AEP, and UNC93B. However, early events initiated by
CpG DNA recognition in DCs leading to the trafficking of TLR9-
UNC93B to the endosomes remain unresolved.746 Immunity 31, 737–748, November 20, 2009 ª2009 Elsevier IncAltogether, our results highlight the primordial role of endo-
cytic proteases, in particular AEP, not only in processing of exog-
enous antigens for MHC class II presentation pathway, but also
in TLR signaling, by perhaps direct proteolysis of endosomal
TLRs. Potent and specific AEP inhibitors have already been
developed, and might be used as therapeutic tools in viral and
inflammatory diseases.
EXPERIMENTAL PROCEDURES
Mice and Cell Preparation
AEP-deficient mice were generated in the lab of C. Peters (Freiburg, Germany)
and backcrossed 11 times on B6 background. Transgenic mice that express
an OVA-specific TCR (OTII) have been previously described (Barnden et al.,
1998). Animals were bred in a pathogen-free environment and were used ac-
cording to the guidelines and regulations of the French Veterinary Department.
Preparation of BMDCs, Macrophages, and Plasmacytoid DCs
Bone-marrow-derived DCs were generated from WT and AEP-deficient mice
by culturing precursors for 7–14 days in GM-CSF-supplemented medium as
previously described (Savina et al., 2006). Bone-marrow-derived macro-
phages were cultured for 6 days in M-CSF-supplemented medium as previ-
ously described (Savina et al., 2006). Cell differentiation was controlled by
FACS staining for CD11c (HL3), CD11b (M1/70), and F4/80 (6F12) antibodies
(all from BD Biosciences). Buffy coats were obtained from adult healthy donors
at the Saint-Antoine Crozatier Blood Bank. Human pDCs were isolated by
using positive selection BDCA-4-conjugated beads (Miltenyi Biotec), as previ-
ously described (Duramad et al., 2005). Mouse splenic pDCs were isolated
with mPDCA-1-based positive selection kit (Miltenyi Biotech). Human pDCs
were 94%–99% BDCA2+ CD123+, and murine pDCs were more than 90%
mPDCA-1+ determined by flow cytometry.
For cytokine secretion assays, cells were plated in 96-well plate and treated
with the indicated concentration of the respective compound for 6 hr. Cytokine
concentration was measured in culture supernatants with home-made (IFN-a
and TNF-a) or commercial (IL-6 and IL-12p40, eBioscience) ELISA kits. LPS
was from Sigma-Aldrich, CpG-B (50-TGACTGTGAACGTTCGAGATGA-30) was
from Trilink Biotechnologies, and CpG-A (50-GGTGCATCGATGCAGGGGGG-
30) and CpG-C (50-TCGTCGAACGTTCGAGATGAT) were a gift from V. Soume-
lis (Institut Curie, Paris, France). AEP inhibitor (MV026630) was kindly provided
by H. Overkleeft (Leiden, Netherlands).
In Vivo DC Stimulation and T Cell Proliferation Assay
Mice were injected i.v. with TLR agonist or PBS alone and bled 2 hr later. Serum
cytokine concentration was assessed by ELISA. Mice received 33 106 CFSE-
labeled lymphocytes i.v. isolated from lymph nodes of Thy1.1 OT II transgenic
Rag/ mice 8–12 hr before injection of OVA-coated beads with or without TLR
agonists as adjuvant. CFSE dilution of injected T lymphocytes in spleen was
analyzed by staining with anti-CD4 (L3T4) and anti-Thy1.1 (OX-7) (BD PharMin-
gen) 48 hr later. Stained cells were acquired on a FACSCalibur and analyzed
with CellQuest (BD Biosciences) or FlowJo (Treestar) software.
Size Chromatography Exclusion, Phagosome Purification, Protease
Activity Measurement, and Immunodetection
503 106 BMDCs were harvested and stimulated in the presence or absence of
CpG (10mg/ml) or LPS (1mg/ml) for different time. Cells were then lysed in 50 mM
Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 0.5% NP40 for 30 min on ice and
centrifuged at 90,000 rpm. The extract was then applied to a G-200 Sephadex
size exclusion column (Pharmacia) and equilibrated in 50 mM Tris (pH 7.4),
150 mM NaCl, 5 mM MgCl2. Fractions were eluted with the same buffer and 5
mg of protein was tested for TLR9, MyD88, and AEP expression by western blot.
For phagosome preparation, 50 3 106 BMDCs were pulsed for 20 min at
37C with magnetic particles (Invitrogen) and then chased at 37C for 100 min
in the presence or absence of CpG (10 mg/ml). For endosome purification, cells
were pulsed for 30 min at 4C with magnetic nanoparticles (kindly given by
C. Menager, Jussieu, Paris, France) and chased at 37C for 30 min with
CpG (10 mg/ml). Cells were then washed with PBS and mechanically disrupted
by passing them through 25 g needle. Phagosomes and endosomes were.
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submitted to separation on a 10% SDS NuPAGE Bis-Tris gels (Invitrogen).
Proteins were transferred on a PVDF membrane and immunodetection was
realized. Rabbit pAb anti-TLR9 (Santa Cruz), mouse anti-human transferrin
receptor, rat anti-LAMP2, and mouse mAb anti-AEP were from PharMingen
and R&D Systems, respectively.
Protease activity assays were performed on a FluoStar Optima (BMG
labtech) by measuring the release of fluorescent N-Acetyl-Methyl-Coumarin
in citrate buffer (pH 5.5) at 37C. Specific substrates for AEP (Z-Ala-Ala-Asn-
NHMec), CatB (Z-Arg-Arg-NHMec), CatB/L (Z-Phe-Arg-NHMec), and CatS
(Z-Val-Val-Arg-NHMec) were from Bachem.
For immunoprecipitation of CatB, L, and S, 100 mg of protein were labeled
with 10 mM of DCG-04 (kind gift by H. Overkleeft, Leiden, Netherlands) for
60 min at 37C. Reaction was stopped by adding sample buffer and boiling
in 1% SDS. Samples were analyzed by 12% SDS-NuPAGE and developed
with HRP-coupled streptavidin (Amersham).
Complementation assays were performed by adding 0.2 mg/106 cells of pro-
CatK to AEP-deficient DCs 30 min before stimulation with different concentra-
tions of CpG. Rabbit pAb anti-CatK was from Santa Cruz.
Endosomal pH Measurement
Endosomal pH measurement has been described (Savina et al., 2006). In brief,
cells were pulsed with 1 mg/ml of FITC- and Alexa-647-labeled 40 kDa
dextrans (Molecular Probes) for 10 min at 37C and extensively washed with
cold PBS plus 1% BSA. Cells were then chased for different times and
analyzed by FACS, via a FL1/FL4 gate selective for cells that have endocy-
tosed the fluorescent probes.
Phagosomal OVA Degradation Assay
3 mm NH2-latex beads (Polyscience, Inc) were covalently coated with OVA
(0.5 mg/ml) according to manufacturer’s instructions. BMDCs were pulsed
for 10 min at 37C and chased for different times at 37C. Cells were lysed
in 50 mM Tris-HCl (pH 7.4) supplemented with 150 mM NaCl, 1 mM DTT,
0.5% NP-40, and cocktail of protease inhibitors (Roche). For FACS analysis,
latex beads were stained with polyclonal anti-OVA (Sigma) and a secondary
anti-rabbit Alexa 647 (Molecular Probes).
35S Labeling of TLR9 Protein, Site-Directed Mutagenesis, Digestion
Assays, and Transfection in DCs
Mouse Tlr9 cDNA (Invivogen) construct was fused at the C terminus to GFP
(pEGFP-N1) and generated by sequential PCR with the primers 50-ccgctagcc-
caccATGGTTCTCCGTCGAAGGA-30 (forward) and 50-cgtcgactgcagaattcgaag
ctTTTCTGCTGTAGGTCCCCGGCAG-30 (reverse). The recombinant C-terminal
Tlr9 fragment encompassing the residues 471–1032 was generated as previ-
ously described (Park et al., 2008). All constructs were cloned into pcDNA3.1
(+) (Invitrogen). Tlr9 cDNA was mutated with the quick change Mutagenesis Kit
(Stratagene) according to the manufacturer’s conditions. For mutagenesis of
Asn 466, sense primer 50-GCTTCTAAGCAGTTCATGGACAGG-30 and antisense
primer 50-CCTGTCCATGAACTGCTTAGAAGC-30 were used.Tlr9GFP was tran-
scribed and translated in vitro with TNT T7 quick Coupled Transcription/Transla-
tion system (Promega) and 10 mCi (35S)methionine (Perkin Elmer). Digestion
assays were performed at 37C in 50 mM citrate buffer (pH 5.5), 0.1% CHAPS,
1 mM DTT, together with 5 ml of translation reaction and recombinant proteases
(AEP, kindly given by C. Watts, Dundee, UK; CatB, D, K, L, and S from Calbio-
chem), or 20 mg of total lysate from WT or AEP-deficient BMDCs in the absence
or presence of the inhibitors: leupeptin 1 mM or MV026630 (50 mM).
106 BMDCs at day 8 were transfected with 1 mg of cDNA coding for GFP,
GFP-tagged Tlr9, N466Q, or C-terminal Tlr9 fragment via the Amaxa kit (Lonza,
Germany). 24 hr later, cells were harvested and stimulated with TLR agonists.
Statistical Analysis
Statistical significance was determined by unpaired t test or one-way ANOVA.
*p < 0.05, **p < 0.01, and ***p < 0.001.
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